首页 | 本学科首页   官方微博 | 高级检索  
     


Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting
Affiliation:1. Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Aberdeen AB25 2ZD, UK;2. Primary Care Franchise, Novartis Pharma AG, Postfach, CH-4002 Basel, Switzerland;3. Novartis Pharma AB, Box 1150, TÄBY, Stockholm S-183 79, Sweden;4. IMS Health Economics and Outcomes Research, 210 Pentonville Road, London N1 9JY, UK;5. Department of Public Health and Caring Sciences, Family Medicine and Preventive Medicine, Uppsala University, Uppsala, Sweden
Abstract:
Keywords:COPD  Costs  Cost-minimisation  Cost-effectiveness  Economic evaluation
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号